UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 6-K
REPORT OF
FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE
SECURITIES EXCHANGE ACT OF 1934
For the month of February 2023
Commission File Number: 001-31995
MEDICURE
INC.
(Translation of registrant's name into English)
2-1250 Waverley Street
Winnipeg, MB Canada R3T 6C6
(Address of principal executive offices)
Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x
Form 40-F o
EXHIBIT
LIST
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| |
Medicure Inc. |
| |
(Registrant) |
| |
|
| |
|
|
| Date: February 1, 2023 |
By: |
/s/ Dr. Albert D. Friesen |
| |
Dr. Albert D. Friesen |
| |
Title: CEO |
Exhibit 99.1
MEDICURE ANNOUNCES RESIGNATION OF BOARD MEMBER
AND GRANT OF STOCK OPTIONS
WINNIPEG, MB, Feb. 1, 2023 /CNW/ - Medicure Inc. ("Medicure"
or the "Company") (TSXV: MPH) (OTC: MCUJF), a company focused on the development and commercialization of pharmaceuticals
and healthcare products for patients and prescribers in the United States market, announced today that Gerald McDole, a member of
the Board of Directors, has resigned from his position, effective January 31, 2023. Mr. McDole was originally appointed a director on
January 16, 2004.
"On behalf of the Board and senior leadership
team, I would like to thank Gerry for his long-standing years of service to the Company, stated Albert Friesen," Chair of Medicure's
Board of Directors. "His experienced guidance and reasoned strategic insights greatly benefited Medicure throughout the years
and we were blessed to have someone of Gerry's character and integrity in a governance position."
The Company also announces that it has granted stock
options (the "Options") to certain directors, officers and employees of the Company to purchase a total of 1,205,000 common
shares at a price of $1.25 per common share. The Options are exercisable for a period of ten years and have been granted in accordance
with the terms of the Company's current stock option plan. The grant of Options is subject to the approval of the TSX Venture Exchange.
About Medicure Inc.
Medicure is a pharmaceutical company focused on the
development and commercialization of therapies for the U.S. cardiovascular market. The present focus of the Company is the marketing and
distribution of AGGRASTAT® (tirofiban hydrochloride) injection and ZYPITAMAG® (pitavastatin) tablets in
the United States, where they are sold through the Company's U.S. subsidiary, Medicure Pharma Inc. Medicure also operates Marley Drug,
Inc. ("Marley Drug"), a pharmacy located in North Carolina that offers an Extended Supply drug program serving all 50 states,
Washington D.C. and Puerto Rico. Marley Drug® is committed to improving the health status of its patients and the communities
they serve while reducing overall health care costs for employers and other health care consumers. For more information visit www.marleydrug.com.
To learn more about The Extended Supply Generic Drug Program call 800.286.6781 or email info@marleydrug.com. For more information
on Medicure please visit www.medicure.com. For additional information about AGGRASTAT®, please visit www.aggrastathdb.com or
refer to the full Prescribing Information. For additional information about ZYPITAMAG®, please visit www.zypitamag.com or
refer to the full Prescribing Information.
To be added to Medicure's e-mail list, please visit:
http://medicure.mediaroom.com/alerts
Neither the TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy
of this release.
Forward Looking Information: Statements contained
in this press release that are not statements of historical fact, including, without limitation, statements containing the words "believes",
"may", "plans", "will", "estimates", "continues", "anticipates", "intends",
"expects" and similar expressions, may constitute "forward-looking information" within the meaning of applicable Canadian
and U.S. federal securities laws (such forward-looking information and forward-looking statements are hereinafter collectively referred
to as "forward-looking statements"). Forward-looking statements, include estimates, analysis and opinions of management of the
Company made in light of its experience and its perception of trends, current conditions and expected developments, as well as other factors
which the Company believes to be relevant and reasonable in the circumstances. Inherent in forward-looking statements are known and unknown
risks, uncertainties and other factors beyond the Company's ability to predict or control that may cause the actual results, events or
developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements,
and as such, readers are cautioned not to place undue reliance on forward-looking statements. Such risk factors include, among others,
the Company's future product revenues, expected results, including future revenue from P5P, the likelihood of receiving a priority review
voucher from the United State Food and Drug Administration, expected future growth in revenues, stage of development, additional capital
requirements, risks associated with the completion and timing of clinical trials and obtaining regulatory approval to market the Company's
products, the ability to protect its intellectual property, dependence upon collaborative partners, changes in government regulation or
regulatory approval processes, and rapid technological change in the industry. Such statements are based on a number of assumptions which
may prove to be incorrect, including, but not limited to, assumptions about: general business and economic conditions; the impact of changes
in Canadian-US dollar and other foreign exchange rates on the Company's revenues, costs and results; the timing of the receipt of regulatory
and governmental approvals for the Company's research and development projects; the availability of financing for the Company's commercial
operations and/or research and development projects, or the availability of financing on reasonable terms; results of current and future
clinical trials; the uncertainties associated with the acceptance and demand for new products and market competition. The foregoing list
of important factors and assumptions is not exhaustive. The Company undertakes no obligation to update publicly or otherwise revise any
forward-looking statements or the foregoing list of factors, other than as may be required by applicable legislation. Additional discussion
regarding the risks and uncertainties relating to the Company and its business can be found in the Company's other filings with the applicable
Canadian securities regulatory authorities or the US Securities and Exchange Commission, and in the "Risk Factors" section of
its Form 20F for the year ended December 31, 2021.
AGGRASTAT® (tirofiban hydrochloride) injection,
ZYPITAMAG® (pitavastatin) tablets, and Marley Drug® are registered trademarks.
View original content:https://www.prnewswire.com/news-releases/medicure-announces-resignation-of-board-member-and-grant-of-stock-options-301735795.html
SOURCE Medicure Inc.
View original content: http://www.newswire.ca/en/releases/archive/February2023/01/c4073.html
%CIK: 0001133519
For further information: Please contact: Dr. Albert Dr. Friesen,
Chief Executive Officer, Tel. 888-435-2220, Fax 204-488-9823, E-mail: info@medicure.com, www.medicure.com
CO: Medicure Inc.
CNW 07:00e 01-FEB-23
This regulatory filing also includes additional resources:
ex991.pdf
Medicure (PK) (USOTC:MCUJF)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
Medicure (PK) (USOTC:MCUJF)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024
